Expert review of vaccines · 2026
The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Neścioruk Magdalena, Kowalska-Duplaga Kinga, Grzybowska-Chlebowczyk Urszula, Sieczkowska Agnieszka, Banaszkiewicz Aleksandra
Аннотация
BACKGROUND: Infectious diseases are known triggers for inflammatory bowel disease (IBD) exacerbations. Although vaccines can prevent many such infections, hesitancy persists among pediatric IBD patients and their caregivers due to concerns about vaccine-induced disease flare-ups. The aim of the study was to evaluate the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on disease activity in children and adolescents with IBD over a 24-month period post-vaccination.
RESEARCH DESIGN AND METHODS: This prospective, multicenter cohort study included IBD patients aged 4-18 years. Participants were assigned to a vaccinated group (single PCV13 dose) or an unvaccinated control group. Disease activity was monitored using PUCAI/PCDAI scores, and exacerbation rates were recorded at 6, 12, 18, and 24 months.
RESULTS: A total of 279 patients (52.3% male; median age, 167 months) were enrolled, of whom 93 (33.3%) received PCV13. The control group showed higher, but not statistically significant, disease activity at any time point (p = 0.06, 0.10, 0.64, 0.36) and exacerbation rates (p = 0.47, 0.17, 0.82, 0.75).
CONCLUSION: A single dose of PCV13 does not increase disease activity in pediatric IBD patients during the 24 months following vaccination.
RESEARCH DESIGN AND METHODS: This prospective, multicenter cohort study included IBD patients aged 4-18 years. Participants were assigned to a vaccinated group (single PCV13 dose) or an unvaccinated control group. Disease activity was monitored using PUCAI/PCDAI scores, and exacerbation rates were recorded at 6, 12, 18, and 24 months.
RESULTS: A total of 279 patients (52.3% male; median age, 167 months) were enrolled, of whom 93 (33.3%) received PCV13. The control group showed higher, but not statistically significant, disease activity at any time point (p = 0.06, 0.10, 0.64, 0.36) and exacerbation rates (p = 0.47, 0.17, 0.82, 0.75).
CONCLUSION: A single dose of PCV13 does not increase disease activity in pediatric IBD patients during the 24 months following vaccination.